CD38 and Miyoshi myopathy: Anti-CD38 MoAb, including daratumumab (DARA), isatuximab (ISA), and MOR202 (Figure 2), have shown tolerability as well as meaningful clinical activity in FDA-approved monotherapy regimens and as components of FDA-approved multi-modality combination regimens for treatment of R/R MM patients [30,34,35,36].